Formulating poorly water soluble drugs. (2016)
- Record Type:
- Book
- Title:
- Formulating poorly water soluble drugs. (2016)
- Main Title:
- Formulating poorly water soluble drugs
- Further Information:
- Note: Robert O. Williams III, Alan B. Watts, Dave A. Miller, editors.
- Editors:
- III, Williams, Robert O, 1956-
Watts, Alan B (Alan Bayard), 1981-
Miller, Dave A - Contents:
- Dedication; Preface; Contents; Contributors; Chapter 1: Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs; 1.1 Introduction; 1.2 Oral Route of Administration; 1.2.1 Challenges in Oral Delivery of Poorly Water-Soluble Drugs; 1.3 Parenteral Route of Administration; 1.3.1 Challenges in Parenteral Delivery of Poorly Water-ƯSoluble Drugs; 1.4 Ocular Route of Administration; 1.4.1 Challenges in Ocular Delivery of Poorly Water-Soluble Drugs; 1.5 Nasal Route of Administration; 1.5.1 Challenges in Nasal Delivery of Poorly Water-Soluble Drugs; 1.6 Pulmonary Route of Administration. 1.6.1 Challenges in Pulmonary Delivery of Poorly Water-ƯSoluble Drugs; 1.7 Summary; References; Chapter 2: Optimizing the Formulation of Poorly Water-ƯSoluble Drugs; 2.1 Introduction; 2.1.1 Solubility Studies; 2.1.1.1 Solubility Prediction; 2.1.2 Experimental Aqueous Solubility Determination; 2.1.3 pH-Solubility Profiles; 2.1.4 Intrinsic Dissolution; 2.1.4.1 Compact Preparation; 2.1.4.2 Intrinsic Dissolution Testing; 2.2 Solid-State Characterization; 2.2.1 Thermal Analysis; 2.2.1.1 Differential Scanning Calorimetry; 2.2.1.2 Flory-Huggins; 2.2.1.3 Thermogravimetric Analysis. 2.2.2 Fourier Transform Infrared Spectroscopy; 2.2.2.1 Sample Preparation; 2.2.2.2 Polymorph Screening; 2.2.2.3 Excipient Interactions; 2.2.3 X-Ray Diffraction; 2.2.3.1 Parameter Selection; 2.2.3.2 Polymorph Screening; 2.2.3.3 Excipient Interactions; 2.2.3.4 Pair Distribution Function (PDF); 2.2.4 Specific SurfaceDedication; Preface; Contents; Contributors; Chapter 1: Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs; 1.1 Introduction; 1.2 Oral Route of Administration; 1.2.1 Challenges in Oral Delivery of Poorly Water-Soluble Drugs; 1.3 Parenteral Route of Administration; 1.3.1 Challenges in Parenteral Delivery of Poorly Water-ƯSoluble Drugs; 1.4 Ocular Route of Administration; 1.4.1 Challenges in Ocular Delivery of Poorly Water-Soluble Drugs; 1.5 Nasal Route of Administration; 1.5.1 Challenges in Nasal Delivery of Poorly Water-Soluble Drugs; 1.6 Pulmonary Route of Administration. 1.6.1 Challenges in Pulmonary Delivery of Poorly Water-ƯSoluble Drugs; 1.7 Summary; References; Chapter 2: Optimizing the Formulation of Poorly Water-ƯSoluble Drugs; 2.1 Introduction; 2.1.1 Solubility Studies; 2.1.1.1 Solubility Prediction; 2.1.2 Experimental Aqueous Solubility Determination; 2.1.3 pH-Solubility Profiles; 2.1.4 Intrinsic Dissolution; 2.1.4.1 Compact Preparation; 2.1.4.2 Intrinsic Dissolution Testing; 2.2 Solid-State Characterization; 2.2.1 Thermal Analysis; 2.2.1.1 Differential Scanning Calorimetry; 2.2.1.2 Flory-Huggins; 2.2.1.3 Thermogravimetric Analysis. 2.2.2 Fourier Transform Infrared Spectroscopy; 2.2.2.1 Sample Preparation; 2.2.2.2 Polymorph Screening; 2.2.2.3 Excipient Interactions; 2.2.3 X-Ray Diffraction; 2.2.3.1 Parameter Selection; 2.2.3.2 Polymorph Screening; 2.2.3.3 Excipient Interactions; 2.2.3.4 Pair Distribution Function (PDF); 2.2.4 Specific Surface Area; 2.2.4.1 BET Surface Area Analysis; 2.2.5 Solid-State Nuclear Magnetic Resonance (SSNMR); 2.2.6 Residual Solvent Analysis; 2.2.6.1 Residual Solvent Guidelines; 2.2.6.2 Analytical Determination of Residual Solvent Levels; 2.3 Stability Testing; 2.3.1 Stability Monitoring. 2.3.2 Chemical Stability; 2.3.3 Stability Testing Conditions; 2.4 Dissolution Testing; 2.4.1 Dissolution Studies; 2.4.1.1 Sample Handling; 2.4.1.2 Excipient Screening for Supersaturation Maintenance Ability; 2.4.1.3 Supersaturation Dissolution Studies; 2.4.1.4 Alternative Dissolution Studies; 2.4.2 In Vivo Testing; 2.4.2.1 Administration Via Inhalation; 2.4.2.2 Oral Administration; 2.5 Conclusions; References; Chapter 3: Solid-State Techniques for Improving Solubility; 3.1 Introduction; 3.2 Pharmaceutical Salts; 3.2.1 Pharmaceutical Salt Selection; 3.2.2 Solubility Enhancement. 3.3 Polymorphs and Amorphous Forms; 3.3.1 Polymorph Preparation; 3.3.2 Amorphous Form Preparation; 3.3.3 Thermodynamics of Metastable Solids; 3.3.4 Solubility and Bioavailability Enhancement; 3.4 Pharmaceutical Co-crystals; 3.4.1 Co-crystal Preparation; 3.4.2 Solubility of Co-crystals; 3.5 Summary; References; Chapter 4: Mechanical Particle-Size Reduction Techniques; 4.1 Introduction; 4.2 Rationale Behind the Reduction of Particle-Size; 4.3 Milling; 4.3.1 Dry Milling; 4.3.1.1 Fluidized Bed Jet Milling; 4.3.1.2 Spiral Jet "Pancake" Mill; 4.3.1.3 Pin Mill. … (more)
- Edition:
- Second edition
- Publisher Details:
- Cham, Switzerland : Springer
- Publication Date:
- 2016
- Extent:
- 1 online resource (xiv, 779 pages), illustrations
- Subjects:
- 615.1/9
Drug development
Drugs -- Design
MEDICAL -- Pharmacology
Drug development
Drugs -- Design
Biomedicine
Pharmaceutical Sciences/Technology
Drug Compounding
Biological Availability
Chemical Phenomena
Chemistry, Pharmaceutical -- methods
Drug Design
Electronic books - Languages:
- English
- ISBNs:
- 9783319426099
3319426095
3319426079
9783319426075 - Related ISBNs:
- 9783319426075
- Notes:
- Note: Includes bibliographical references and index.
Note: Print version record. - Access Rights:
- Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
- Access Usage:
- Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD.DS.382218
- Ingest File:
- 02_363.xml